Scynexis Reports Phase 1 Study Results for Autosomal Dominant Polycystic Kidney Disease Treatment

SCYNEXIS Inc. has announced Phase 1 study results for Scy-770, an oral direct AMPK activator intended for the treatment of Autosomal Dominant Polycystic Kidney Disease.